Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD), albeit in a confined breast cancer indication like Menarini’s drug before it. More: Eli Lilly's oral SERD Inluriyo passes muster with FDA in breast
read moreThe FDA on Thursday signed off on Crinetics’ paltusotine—now christened Palsonify—as a first-line treatment for certain adults with acromegaly. Unlike other somatostatin drugs that make up the bulk of current acromegaly care options, Palsonify is a small molecule, non-peptide therapy
read moreHansa Biopharma has reported positive top-line results from a U.S. phase 3 trial of its antibody-cleaving enzyme imlifidase, which boasts conditional nods in the EU and several other countries to ease the kidney transplant process for certain patients with end-stage
read moreOn the heels of the launch of an online direct-to-patient program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP project. More: BMS plots another DTC platform, this one
read moreWith an appeal to the Supreme Court, AstraZeneca is throwing one last Hail Mary following a string of Big Pharma defeats challenging the legality of the Inflation Reduction Act (IRA) Medicare price negotiation program. More: With SCOTUS appeal, AstraZeneca makes
read more© 1994 - 2025 B.M. Pharmaceuticals